Analysen von Emmanuel Papadakis
26.03.18 | GSK overweight | Barclays Capital | |
09.03.18 | Fresenius overweight | Barclays Capital | |
09.03.18 | Fresenius Medical Care (FMC) St. Equal weight | Barclays Capital | |
09.03.18 | Bayer Underweight | Barclays Capital | |
08.03.18 | Novo Nordisk Underweight | Barclays Capital | |
05.03.18 | Bayer Underweight | Barclays Capital | |
20.02.18 | Novartis Underweight | Barclays Capital | |
20.02.18 | Sanofi Underweight | Barclays Capital | |
Werbung
|
|||
05.02.18 | Roche overweight | Barclays Capital | |
25.01.18 | Novartis Underweight | Barclays Capital | |
23.01.18 | Sanofi Underweight | Barclays Capital | |
22.01.18 | Bayer Underweight | Barclays Capital | |
17.01.18 | GSK overweight | Barclays Capital | |
03.01.18 | Bayer Underweight | Barclays Capital | |
21.12.17 | Roche overweight | Barclays Capital | |
06.12.17 | Bayer Underweight | Barclays Capital | |
17.11.17 | Bayer Underweight | Barclays Capital | |
15.11.17 | Sanofi Equal weight | Barclays Capital | |
15.11.17 | Novo Nordisk Underweight | Barclays Capital | |
07.11.17 | Bayer Underweight | Barclays Capital | |
06.11.17 | Bayer Underweight | Barclays Capital | |
27.10.17 | GSK Equal weight | Barclays Capital | |
25.10.17 | Novartis Underweight | Barclays Capital | |
13.09.17 | Roche overweight | Barclays Capital | |
13.09.17 | AstraZeneca overweight | Barclays Capital | |
10.08.17 | Novo Nordisk Underweight | Barclays Capital | |
03.07.17 | AstraZeneca overweight | Barclays Capital | |
23.06.17 | Novartis Equal weight | Barclays Capital | |
13.06.17 | Roche overweight | Barclays Capital | |
02.06.17 | Novartis Underweight | Barclays Capital | |
19.05.17 | Roche overweight | Barclays Capital | |
19.05.17 | Roche overweight | Barclays Capital | |
08.05.17 | Sanofi Underweight | Barclays Capital | |
08.03.17 | Novo Nordisk Underweight | Barclays Capital | |
08.03.17 | Roche overweight | Barclays Capital | |
08.03.17 | Sanofi Underweight | Barclays Capital | |
08.03.17 | GSK Equal weight | Barclays Capital | |
08.03.17 | AstraZeneca overweight | Barclays Capital |